JIM Think Tank: Are innovative payment models required to give patients access to potential disease-modifying therapies for Alzheimer's disease?

Several potentially disease-modifying therapies for Alzheimer's disease (AD) are currently in final stages of clinical development. If such drugs obtain regulatory approval, difficult questions will need to be answered regarding how these treatments should and could be paid for. Reimbursement challenges are not unique to the field of AD; however, the scale of the issue would be unparalleled due to the high prevalence, enormous unmet medical need and combination of complexities involved in determining the value of a novel disease-modifying AD treatment and aligning the incentives of the multiple stakeholders involved.

The costs for caring for people with dementia are split across different systems (health care, social care, unpaid informal care); such 'silos' can cause suboptimal incentives for introducing new therapies. Reimbursing a disease-modifying AD treatment means paying today for uncertain future benefits; for patients with early disease many years may pass until full treatment benefits are realized, e.g. delays in progression to late-stage dementia. The differential timing between costs and issues can create issues for reimbursement in health care systems operating on short time horizons and where patients frequently move between insurance plans. Although clinical benefits will have been demonstrated in registrational trials, considerable uncertainty is likely to remain at the time reimbursement decisions need to be made. Effects on long-term endpoints such as mortality or institutionalization will be unknown but are critically important in determining the value of the disease-modifying therapy.

A selection of non-standard payment mechanisms has been proposed as potential solutions to these issues, such as pay-for-performance schemes, annuity and subscription pricing structures, securitization of outcomes-based contracts (health impact bonds) and other innovations. This workshop will explore the potential for innovative payment models to address the combination of issues relating to the reimbursement of disease-modifying therapies for AD, drawing on learnings from other fields such as oncology and rare diseases.

Aim: This JIM Think Tank will provide a critical assessment of the applicability of innovative/alternative payment models to disease-modifying AD treatments, and develop proposals for which pricing model(s) to consider under different circumstances.

Date : November 11, 2022

Location : Nobel Forum, Karolinska Institutet, Stockholm, Sweden

Admission : Free, **pre-registration required to** gunilla.johansson@ki.se (number of participants limited)

Agenda

Time	Title	Speakers
09.00-09.15	Welcome	Bengt Winblad, Karolinska Institutet
09.15-09.30	Introduction to workshop and objectives	Linus Jönsson, Karolinska Institutet
09.30-09.45	The socioeconomic impact of Alzheimer's Disease	Anders Wimo, Karolinska Institutet
09.45-10.15	Determining the value of disease-modifying therapies for Alzheimer's Disease	Will Herring, RTI and Karolinska Institutet
10.15-10.45	What are the challenges with reimbursement of disease-modifying therapies for Alzheimer's Disease?	Niklas Hedberg, Dental and Pharmaceutical Benefits Agency, chair of EUnetHTA.
10.45-11.15	Coffee break	
11.15-11.45	Experience with outcomes-based payment models in chronic progressive disease	Amanda Cole, Office of Health Economics
11:45-12:00	Questions, discussion	
12.00-13.00	Lunch	
13.00-13.30	Innovative payment models: beyond payment for outcomes	Joakim Ramsberg, Swedish Brain Foundation
13.30-14.00	Innovative payment models – the US experience	Mark McClellan, Duke University
14.00-15.00	Industry panel: innovative payment models, promises and experiences	Chair: Linus Jönsson Panel members to be announced later
15.00-15.30	Coffee break	
15.30-16.00	Real-world data for outcomes-based reimbursement schemes in AD	Pieter-Jelle Visser, UMC Amsterdam
16:00-16:45	Roundtable discussion: future payment models for AD therapies	All speakers
16:45-17:00	Wrap-up and conclusions	Bengt Winblad, Linus Jönsson Karolinska Institutet